253 - References

References

256 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

1. Paciullo CA. Evaluating the association between clozapine and venous thromboembolism. Am J Health Syst Pharm 2008; 65:1825–1829.
2. Walker AM, et al. Mortality in current and former users of clozapine. Epidemiology 1997; 8:671–677.
3. Hagg S, et al. Association of venous thromboembolism and clozapine. Lancet 2000; 355:1155–1156.
4. Davis S, et al. Antiphospholipid antibodies associated with clozapine treatment. Am J Hematol 1994; 46:166–167.
5. Axelsson S, et al. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin Exp Pharmacol Physiol 2007; 34:775–780.
6. Sarvaiya N, et al. Clozapine-­associated pulmonary embolism: a high-­mortality, dose-­independent and early-­onset adverse effect. Am J Ther 2018; 25:e434–e438.
7. Allenet B, et al. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf 2012; 21:42–48.
8. Huang J, et al. Association between antipsychotics and pulmonary embolism: a pharmacovigilance analysis. Expert Opin Drug Saf 2024; doi: 10.1080/14740338.2024.2396390.
9. Dai L, et al. The association and influencing factors between antipsychotics exposure and the risk of VTE and PE: a systematic review and meta-­analysis. Curr Drug Targets 2020; 21:930–942.
10. Lacut K. Association between antipsychotic drugs, antidepressant drugs, and venous thromboembolism. Clin Adv Hematol Oncol 2008; 6:887–890.
11. Masopust J, et  al. Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry Clin Neurosci 2012; 66:541–552.
12. Jonsson AK, et al. Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management. CNS Drugs 2012; 26:649–662.
13. Maly R, et al. Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients. Psychiatry Clin Neurosci 2008; 62:3–8.
14. Ronaldson KJ. Cardiovascular disease in clozapine-­treated patients: evidence, mechanisms and management. CNS Drugs 2017; 31:777–795.
15. Khan AA, et  al. Clozapine and incidence of myocarditis and sudden death: long term Australian experience. Int J Cardiol 2017; 238:136–139.
16. Youssef DL, et al. Incidence and risk factors for clozapine-­induced myocarditis and cardiomyopathy at a regional mental health service in Australia. Australas Psychiatry 2016; 24:176–180.
17. Tirupati S, et al. High rates of myocarditis with clozapine in the Hunter region of Australia. Schizophr Res 2024; 264:543–548.
18. Cohen D, et  al. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry 2012; 73:1307–1312.
19. Kilian JG, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354:1841–1845.
20. Freudenreich O. Clozapine-­induced myocarditis: prescribe safely but do prescribe. Acta Psychiatr Scand 2015; 132:240–241.
21. Ronaldson KJ, et al. Clozapine-­induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand 2015; 132:231–240.
22. Qubad M, et al. When, why and how to re-­challenge clozapine in schizophrenia following myocarditis. CNS Drugs 2024; 38:671–696.
23. Siskind D, et al. Systematic review and meta-­analysis of rates of clozapine-­associated myocarditis and cardiomyopathy. Aust N Z J Psychiatry 2020; 54:467–481.
24. La Grenade L, et al. Myocarditis and cardiomyopathy associated with clozapine use in the United States [Letter]. N Engl J Med 2001; 345:224–225.
25. Marder SR, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334–1349.
26. Annamraju S, et al. Early recognition of clozapine-­induced myocarditis. J Clin Psychopharmacol 2007; 27:479–483.
27. Wehmeier PM, et al. Chart review for potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine. J Child Adolesc Psychopharmacol 2004; 14:267–271.
28. McNeil JJ, et al. Clozapine-­induced myocarditis: characterisation using case-­control design. Eur Heart J 2013; 34 Suppl 1:688.
29. Richardson N, et al. Clozapine-­induced myocarditis and patient outcomes after drug rechallenge following myocarditis: a systematic case review. Psychiatry Res 2021; 305:114247.
30. Reinders J, et al. Clozapine-­related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry 2004; 38:915–922.
31. Manu P, et al. Clozapine rechallenge after major adverse effects: clinical guidelines based on 259 cases. Am J Ther 2018; 25:e218–e223.
32. Bellissima BL, et al. A systematic review of clozapine-­induced myocarditis. Int J Cardiol 2018; 259:122–129.
33. Nguyen B, et al. Successful clozapine re-­challenge following myocarditis. Australas Psychiatry 2017; 25:385–386.
34. Otsuka Y, et al. Clozapine-­induced myocarditis: follow-­up for 3.5 years after successful retrial. J Gen Fam Med 2019; 20:114–117.
35. Noël MC, et  al. Clozapine-­related myocarditis and rechallenge: a case series and clinical review. J Clin Psychopharmacol 2019; 39:380–385.
36. Hosseini SA, et al. Successful clozapine re-­challenge after suspected clozapine-­induced myocarditis. Am J Case Rep 2020; 21:e926507.
37. Rostagno C, et al. Beta-­blocker and angiotensin-­converting enzyme inhibitor may limit certain cardiac adverse effects of clozapine. Gen Hosp Psychiatry 2008; 30:280–283.
38. Floreani J, et al. Successful re-­challenge with clozapine following development of clozapine-­induced cardiomyopathy. Aust N Z J Psychiatry 2008; 42:747–748.
39. Patel RK, et al. Clozapine and cardiotoxicity: a guide for psychiatrists written by cardiologists. Psychiatry Res 2019; 282:112491.

Schizophrenia and related psychoses CHAPTER 1 40. Roh S, et al. Cardiomyopathy associated with clozapine. Exp Clin Psychopharmacol 2006; 14:94–98. 41. Masopust J, et al. Repeated occurrence of clozapine-­induced myocarditis in a patient with schizoaffective disorder and comorbid Parkinson’s disease. Neuro Endocrinol Lett 2009; 30:19–­21. 42. Ronaldson KJ, et al. Observations from 8 cases of clozapine rechallenge after development of myocarditis. J Clin Psychiatry 2012; 73:252–­254. 43. Nielsen J, et al. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? 2013; 74: 603–613; quiz 613. 44. Holden J, et al. Successful rechallenge after clozapine-­associated myocarditis. BMJ Case Rep 2022; 15:e248909. 45. Hassan I, et al. Monitoring in clozapine rechallenge after myocarditis. Australas Psychiatry 2011; 19:370–371. 46. Bray A, et al. Successful clozapine rechallenge after acute myocarditis. Aust N Z J Psychiatry 2011; 45:90. 47. Rosenfeld AJ, et al. Successful clozapine retrial after suspected myocarditis. Am J Psychiatry 2010; 167:350–351. 48. Ronaldson KJ, et al. Clinical course and analysis of ten fatal cases of clozapine-­induced myocarditis and comparison with 66 surviving cases. Schizophr Res 2011; 128:161–165. 49. Ronaldson KJ, et al. A new monitoring protocol for clozapine-­induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry 2011; 45:458–465. 50. Griffin JM, et al. Clozapine-­associated myocarditis: a protocol for monitoring upon clozapine initiation and recommendations for how to conduct a clozapine rechallenge. J Clin Psychopharmacol 2021; 41:180–185. 51. De Las Cuevas C, et al. Clozapine-­associated myocarditis in the World Health Organization’s pharmacovigilance database: focus on reports from various countries. Rev Psiquiatr Salud Ment (Engl Ed) 2022; 15:238–250. 52. Segev A, et al. Clozapine-­induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy. Br J Psychiatry 2021; 219:644–651. 53. Robinson G, et al. Echocardiography and clozapine: is current clinical practice inhibiting use of a potentially life-­transforming therapy? Aust Fam Physician 2017; 46:169–170. 54. Knoph KN, et al. Clozapine-­induced cardiomyopathy and myocarditis monitoring: a systematic review. Schizophr Res 2018; 199:17–30. 55. Vickers M, et al. Risk factors for clozapine-­induced myocarditis and cardiomyopathy: a systematic review and meta-­analysis. Acta Psychiatr Scand 2022; 145:442–455. 56. Ronaldson KJ, et al. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-­control study. Schizophr Res 2012; 141:173–178. 57. Coulter DM, et  al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001; 322:1207–1209. 58. Zhang S, et al. Exploration of clozapine-­induced cardiomyopathy and its mechanism. Cardiovasc Toxicol 2024; 24:1192–1203. 59. Curto M, et al. Systematic review of clozapine cardiotoxicity. Curr Psychiatry Rep 2016; 18:68. 60. Pastor CA, et al. Masked clozapine-­induced cardiomyopathy. J Am Board Fam Med 2008; 21:70–74. 61. Sagar R, et al. Clozapine-­induced cardiomyopathy presenting as panic attacks. J Psychiatr Pract 2008; 14:182–185. 62. Nederlof M, et al. Clozapine re-­exposure after dilated cardiomyopathy. BMJ Case Rep 2017; 2017:bcr2017219652. 63. Alawami M, et al. A systematic review of clozapine induced cardiomyopathy. Int J Cardiol 2014; 176:315–320. 64. Williams F, et al. Continuing clozapine treatment after a diagnosis of cardiomyopathy. Ir J Psychol Med 2021; 38:227–231. 65. Grover S, et al. Safe use of clozapine in a patient with treatment resistant schizophrenia with co-­morbid dilated cardiomyopathy: a case report. Asian J Psychiatr 2022; 68:102971. 66. Whiskey E, et  al. Resolution without discontinuation: heart failure during clozapine treatment. Ther Adv Psychopharmacol 2020; 10:2045125320924786. 67. Modai I, et  al. Sudden death in patients receiving clozapine treatment: a preliminary investigation. J Clin Psychopharmacol 2000; 20:325–327. 68. Kang UG, et al. Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry 2000; 61:441–446. 69. Thomassen R, et al. Antipsychotic drugs and venous thromboembolism [Letter]. Lancet 2000; 356:252. 70. Hagg S, et al. Antipsychotic-­induced venous thromboembolism: a review of the evidence. CNS Drugs 2002; 16:765–776. 71. Ronaldson KJ, et al. Diagnostic characteristics of clozapine-­induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry 2010; 71:976–981. 72. Yuen JWY, et  al. Clozapine-­induced cardiovascular side effects and autonomic dysfunction: a systematic review. Front Neurosci 2018; 12:203.